Publications by authors named "Anja Oer Knudsen"
Article Synopsis
- The management of advanced ovarian cancer (AOC) has improved due to molecular diagnostics that help predict how patients will respond to PARP inhibitors, particularly based on homologous recombination deficiency (HRD) status.
- This study analyzed tumor samples from a clinical trial to investigate why HRD status isn't always a reliable indicator of sensitivity to PARP inhibitors.
- Key findings included that some HRD-negative samples showed responses to treatment despite their status, while some HRD-positive samples did not, emphasizing the need to consider other genetic factors beyond HRD status.
Objectives: There are few data on Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in women with primary unresectable or recurrent platinum-resistant peritoneal metastasis (PM) from ovarian cancer (OC). We evaluated survival, histological and cytological response, Quality of Life (QoL) and toxicity after PIPAC C/D in these patients.
Methods: Retrospective analysis of patients from the prospective PIPAC-OPC1 and -OPC2 studies.